| Sophia Galustian, | |
|
2411 Holmes St, Kansas City, MO 64108-2741 | |
| (816) 235-5172 | |
| Not Available |
| Full Name | Sophia Galustian |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 22 Years |
| Location | 2411 Holmes St, Kansas City, Missouri |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841672110 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 2018023714 (Missouri) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Crystal Run Healthcare Physicians Llp | 6901792696 | 395 |
News Archive
Two SIM USA physicians — one a long-term veteran and the second a new, short-term volunteer — are headed to Ebola-stricken West Africa and available to speak this week in advance of International Volunteer Day, Dec. 5, on a variety of topics related to the outbreak, the healthcare crisis in the region, and the role and need for volunteers.
Expectant mothers need not be concerned that they are more prone to develop melanoma, or will have a worse prognosis if they do get this serious skin cancer, than women who are not pregnant, according to study results published online as an "article in press" on the Journal of the American College of Surgeons website ahead of print publication.
Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.
According to a study done by the Pancreatic Cancer Action Network and published by the Cancer Research Journal, early detection for Pancreatic Cancer is particularly important because it is known as the "silent killer", by the time symptoms appear it is usually too late and is known to have a very low survival rate of 7% over 5 years.
Increased life expectancy implies fundamental changes in the composition of populations, with a significant rise in the number of elderly people. These changes are likely to have a massive influence on the life of individuals and on society in general.
› Verified 9 days ago
| Entity Name | Crystal Run Healthcare Physicians Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952376410 PECOS PAC ID: 6901792696 Enrollment ID: O20040227000791 |
News Archive
Two SIM USA physicians — one a long-term veteran and the second a new, short-term volunteer — are headed to Ebola-stricken West Africa and available to speak this week in advance of International Volunteer Day, Dec. 5, on a variety of topics related to the outbreak, the healthcare crisis in the region, and the role and need for volunteers.
Expectant mothers need not be concerned that they are more prone to develop melanoma, or will have a worse prognosis if they do get this serious skin cancer, than women who are not pregnant, according to study results published online as an "article in press" on the Journal of the American College of Surgeons website ahead of print publication.
Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.
According to a study done by the Pancreatic Cancer Action Network and published by the Cancer Research Journal, early detection for Pancreatic Cancer is particularly important because it is known as the "silent killer", by the time symptoms appear it is usually too late and is known to have a very low survival rate of 7% over 5 years.
Increased life expectancy implies fundamental changes in the composition of populations, with a significant rise in the number of elderly people. These changes are likely to have a massive influence on the life of individuals and on society in general.
› Verified 9 days ago
| Entity Name | St John's Medical Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023042173 PECOS PAC ID: 1850314865 Enrollment ID: O20060105000203 |
News Archive
Two SIM USA physicians — one a long-term veteran and the second a new, short-term volunteer — are headed to Ebola-stricken West Africa and available to speak this week in advance of International Volunteer Day, Dec. 5, on a variety of topics related to the outbreak, the healthcare crisis in the region, and the role and need for volunteers.
Expectant mothers need not be concerned that they are more prone to develop melanoma, or will have a worse prognosis if they do get this serious skin cancer, than women who are not pregnant, according to study results published online as an "article in press" on the Journal of the American College of Surgeons website ahead of print publication.
Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.
According to a study done by the Pancreatic Cancer Action Network and published by the Cancer Research Journal, early detection for Pancreatic Cancer is particularly important because it is known as the "silent killer", by the time symptoms appear it is usually too late and is known to have a very low survival rate of 7% over 5 years.
Increased life expectancy implies fundamental changes in the composition of populations, with a significant rise in the number of elderly people. These changes are likely to have a massive influence on the life of individuals and on society in general.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sophia Galustian, 374 Stockholm St, Brooklyn, NY 11237-4006 Ph: (718) 963-7272 | Sophia Galustian, 2411 Holmes St, Kansas City, MO 64108-2741 Ph: (816) 235-5172 |
News Archive
Two SIM USA physicians — one a long-term veteran and the second a new, short-term volunteer — are headed to Ebola-stricken West Africa and available to speak this week in advance of International Volunteer Day, Dec. 5, on a variety of topics related to the outbreak, the healthcare crisis in the region, and the role and need for volunteers.
Expectant mothers need not be concerned that they are more prone to develop melanoma, or will have a worse prognosis if they do get this serious skin cancer, than women who are not pregnant, according to study results published online as an "article in press" on the Journal of the American College of Surgeons website ahead of print publication.
Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.
According to a study done by the Pancreatic Cancer Action Network and published by the Cancer Research Journal, early detection for Pancreatic Cancer is particularly important because it is known as the "silent killer", by the time symptoms appear it is usually too late and is known to have a very low survival rate of 7% over 5 years.
Increased life expectancy implies fundamental changes in the composition of populations, with a significant rise in the number of elderly people. These changes are likely to have a massive influence on the life of individuals and on society in general.
› Verified 9 days ago
Maria Akram Sheikh, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-0340 Fax: 816-932-3148 | |
Dr. Philip Barigbi Augustine, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4150 N Mulberry Dr, Kansas City, MO 64116 Phone: 816-912-4539 Fax: 855-813-6642 | |
Lucas Vocelka, DO Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2340 E Meyer Blvd, Bldg 2, Suite 392, Kansas City, MO 64132 Phone: 816-444-7977 Fax: 630-528-9578 | |
Karla L Houston-gray, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1004 Carondelet Dr Ste 300, Kansas City, MO 64114 Phone: 816-942-4500 Fax: 816-941-4504 | |
Carl D Dirks, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4320 Wornall Rd, Suite 65, Kansas City, MO 64111 Phone: 816-932-6100 Fax: 816-932-9002 | |
Michelle L Dew, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 4330 Wornall Rd, Suite 2000, Kansas City, MO 64111 Phone: 816-931-1883 Fax: 816-756-3645 | |
Brenda J Rogers, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2401 Gillham Rd, Kansas City, MO 64108 Phone: 816-234-3000 |